WO1991002725A1 - Derivatives of 5-amino-1,2,3,4 tetrahydro-acridine and applications as drugs - Google Patents

Abstract

Chemical compounds derived from 5-amino-1,2,3,4-tetrahydroacridine (THA) having the general formula (I) wherein R may represent a glycosyl group such as ascorbate, a substituted glycosyl group such as an inosinyle, adenosinyle or guanidosinyle group, a thio-carbamyl group, an adamantyl group, an isatinyl group, an alpha-cetoglutaryl group, H2?Z group, wherein Z is a residu of a monoacid or a diacid in ionic form and non covalently bound to the molecule of the compound, said acid being optionally parachlorophenoxy-aceate or pamoate or a hydrogen atom in which case the compound is present in the form of a complex comprising at least a THA molecule associated with at least one molecule selected amongst alpha-adamantane, alpha-amino-adamantane and a nucleoside. These molecules are intended to the treatment of AIDS, degenerative or atrophic diseases, particularly senile dementia of the Alzheimer type, multiple sclerosis or Duchesne myopathy. The ascorbate of THA may be given by parenteral or intraveinous administration.

Description

 Derivatives of 5-amino-1,2,3, -tétra ydro-acridine and applications as medicaments.

The invention relates to derivatives of 5-amino 1,2,3,4-tetrahydroacridine and the applications of these substances as medicaments.

The THA molecule, as well as methods for obtaining this molecule, are already described in the literature. We find in particular the reference of this product in the Merck index n ° 89 07, 10th edition (July 1983), under the name Tacrine. Depending on the nomenclature adopted for writing the chemical formula, THA can also be called 9-amino 1,2,3,4-tetrahydroacridine.

We already know that this molecule can be used, in addition to its applications of anticholinesterase and respiratory stimulant, in the treatment of different forms of degeneration, in particular against Alzheimer's disease which causes serious mental disorders in certain old people. However, until recently, THA treatment had very significant drawbacks due in particular to the toxicity of certain impurities present in the available THA preparations. On the other hand, N-substituted derivatives of THA are known, in particular the salts of THA para-chlorophenoxyacetate and THA para-bromophenoxyacetate which are used in the treatment of pathological conditions directly or indirectly produced by cerebral anoxia (Special Drug Patent FR-M-3.860).

The object of the present invention is to provide derivatives of THA having on the one hand a low toxicity and on the other hand an increased biological activity and specificity compared with unsubstituted THA, in particular with regard to its activity virulicide.

dans laquelle :The subject of the invention is therefore chemical compounds derived from 5-amino 1,2,3,4-tetrahydroacridine (THA) corresponding to the general formula:

in which :

R represents - a glycosyl group optionally substituted by a purine base,

a thio-carbamyl group, in which case said group is common to two molecules of THA which are linked to it by the group -NH in position 5, an optionally substituted adamantyl group,

- an isatinyl group,

- an alpha ketoglutaryl group,

an H ₂ Z group, in which Z represents a residue of a monoacid or of a diacid, in ionic form and linked in a non-covalent manner to the molecule of the compound,

- a hydrogen atom, in which case the compound is present in the form of a complex comprising at least one THA molecule associated with at least one molecule chosen from alpha-adamantane, alpha-amino adamantane and a nucleoside such as l adenosine, guanosine or inosine. "These compounds can be in the form of racemic mixtures or in the form of stereoisomers.

The compounds for which R is different from H ₂ Z can also be in the form of pharmaceutically acceptable salts.

If R represents a glycosyl group, said group can be an ascorbyl group. It should be noted that HAT ascorbate is water-soluble, which allows its intramuscular (i.m.), intravenous (i.v.) or subcutaneous (s.c.) injection or its infusion.

If R represents a substituted glycosyl group, said group can be an inσsinyl, adenosine or guanidosinyl group, optionally substituted.

If R represents a thio-carba yl group, said compound can be a di (tetrahydro 1,2,3,4-acrydinyl-5) thio urea.

If R represents an adamantanyl group, said group can be an alpha-adamantanyl or alpha-amino-adamantanyl group.

If R represents an H ₂ Z group, said compound may be in the form of a THA pamoate salt.

According to the invention, it is possible to associate with THA molecules having a known pharmacological activity, for example virulicide, so as to potentiate the effects of THA or to facilitate its application as a medicament, in particular the practical methods of its administration.

These compounds can be obtained by preparation methods known to those skilled in the art, in particular by simultaneous dissolution of THA and of another reagent in a solvent or by simultaneous spraying of THA and of another reagent in a mortar .

The invention also relates to medicaments containing at least one of these compounds or a para-chlorophenoxyacetate salt of HAT, in particular medicaments for the treatment of degenerative or atrophic diseases, such as AIDS, senile dementias of the Alsheimer type, multiple sclerosis or Du chesne myopathy.

The present invention also relates to a pharmaceutical composition containing an effective amount of at least one of the compounds or of a para-chlorophenoxy acetate THA salt previously described, in combination with one or more compatible and pharmaceutically acceptable diluents or adjuvants. .

Such compositions are particularly intended for the treatment of degenerative or atrophic diseases ques, in particular of the Alzheimer type, multiple sclerosis, Duchesne's myopathy as well as AIDS. Preferably, this composition is presented for oral, parenteral or intravenous administration. The invention further relates to a method of treating degenerative or atrophic diseases, in particular senile dementias of the Alzheimer type, multiple sclerosis, Duchesne's myopathy and AIDS by administration of at least one of the compounds. previously described or of a para-chloro-phenoxyacetate salt of THA.

The routes of administration of such compounds are those customary for these types of treatment, in particular by oral, parenteral or intravenous route.

The invention will be further illustrated without being in any way limited by the following description and in particular by the following Figures:

Figures 1 and 20 respectively representing the nuclear magnetic resonance (NMR) spectra of the HBA ascorbate and of the final compound of Example 11. Figures 2, 4, 7, 9, 10, 11, 13, 15 , 17 and 19 representing the infrared spectra (IR) of the compounds described in examples 1, 2, 4, 5, 6, 7, 8, 9, 10 and 11. Figures 3, 5, 6, 8, 12, 14 , 16 and 18 represent the Ultraviolet (UV) spectra obtained on a BECKMANN-D64 spectrophotometer of the compounds described in examples 1, 2, 3, 4, 7, 8, 9, 10.

L'ascorbate de THA peut être représenté par la formule développée (I) :

Example 1 - Preparation and characterization of ascorbate

THA ascorbate can be represented by the structural formula (I):

2 g of THA base are dissolved in 20 ml of 50% ethanol by volume, and the solution thus obtained is warmed up in a water bath for 10 minutes so as to dissolve the THA; the pH of this solution is then about 10. Simultaneously, 1.80 g of ascorbic acid is dissolved in 10 ml of a 50% by volume ethanol solution (pH of solution 2 to 3).

The two solutions are then mixed and a final pH of between 5 and 7 is obtained. Two characteristic effects are observed, on the one hand an exothermic effect, the mixture of the two solutions giving off heat, and on the other hand a bathochro effect, the two constituents being colorless and the final product being yellow or yellowish. The excess solvent is removed in a water bath under vacuum until dry.

A light yellow microcrystalline powder is then obtained, soluble in water, in alcohols and in glycols, and having a melting point in capillary tube of 174 ° C. The elementary analysis of the product obtained is as follows:

The NMR spectrum of the product in D ₂ 0 shown in Figure 1 is obtained on VARI N-60 by dissolving 10 mg of THA ascorbate in 1 ml of heavy water. Its infrared spectrum is shown in Figure 2 and its UV spectrum is shown in Figure 3. It shows characteristic bands at around 215 nm, 245 nm and 320 nm. Example 2 - Preparation and characterization of THA parachlorophenoxyacetate (C _{? 1} H _{? 1} N, 0 ^ Cl) THA parachlorphenoxy acetate can be represented by the structural formula (II)

1 g of freshly prepared THA base is dissolved in 25 ml of absolute ethyl alcohol, slightly warming; the

PH of the solution is then 10. Simultaneously, we dissolve 0.94 g of parachlorophenoxyacetic acid in 10 ml of absolute ethanol (pH of solution 4).

Under magnetic stirring, the two solutions previously obtained are mixed and after an exothermic and bathochrome reaction, the pH is approximately 7.

It is left overnight and the excess ethanol is removed in a water bath under vacuum until dry.

This gives a yellow viscous mass which crystallizes slowly. The compound is in the form of fine colorless crystals, soluble in alcohols and glycols, and having a melting point of 68 ° C. The centesimal analysis gives the following results: Carbon% 65.54 Hydrogen% 5.50 Nitrogen% 7.29

Chlorine% 9.22

The infrared spectrum of the final compound is shown in Figure 4 and the UV spectrum in Figure 5, highlighting 4 characteristic peaks at 282 nm, 252 nm, 248 nm and 206 nm.

La di(té rahydro-l,2,3,4 acridinyl-5) thio urée peut être représentée par la formule développée (III)Example 3 - Preparation and characterization of _.__ diftétra- hydro 1,2,3,4 acridinyl-5) thio-urea

The di (te rahydro-l, 2,3,4 acridinyl-5) thio urea can be represented by the structural formula (III)

(III)

On ajoute à froid 4 g de THA base dans 50 m d'éthanol absolu, dans un récipient de 150 ml muni d'u réfrigérant, d'une agitation magnétique, et pouvant êtr chauffé au bain-marie. On tiédit légèrement la solution pou dissoudre toute la THA. On refroidit et on introduit 5 ml d sulfure de carbone.

4 g of THA base is added in cold in 50 m of absolute ethanol, in a 150 ml container fitted with a cooler, with magnetic stirring, and which can be heated in a water bath. The solution is slightly warm to dissolve all the HAT. It is cooled and 5 ml of carbon sulfide are introduced.

Then stirred with magnetic stirring and gently heated for 2 hours. The excess solvent is removed in a water bath under vacuum and a yellow viscous paste is obtained which recrystallizes from a cool hydroal solution.

The product obtained is in the form of a yellow microcrystalline powder having a melting point of 268 ° C. The centesimal analysis of the product is as follows:

Carbon% 74.03 Hydrogen% 5.98 Nitrogen% 12.79 Chlorine% 7.32 The UV spectrum is represented in Figure 6 and the o notices 4 characteristic peaks at 215 nm, 241.5 nm, 324.5 n and 336.5 nm.

Example 4 - Preparation and characterization of THA pamoate fÇ _M HN, 0 ^ THA pamoate can be represented by the following developed formula (IV):

(IV)

2 g of pamoic acid are dissolved in 20 ml of a 50% aqueous pyridine solution (pH = 5).

2 g of freshly obtained THA base are dissolved simultaneously in 20 ml of a 50% aqueous pyridine solution; the final pH is around 10.

The two solutions are mixed with magnetic stirring and after an exothermic reaction a p of approximately 6 to 8 is obtained.

Then concentrated in a vacuum water bath, using a water pump, until dry.

The product obtained is in the form of fine colorless crystals soluble in alcohols and glycol and having a melting point of 256 ° C. The centesimal analysis gives the following results: Carbon% 73.70 Hydrogen% 5.15 Nitrogen% 4.77

The infrared spectrum of the compound is shown in Figure 7 and its UV spectrum in Figure 8, highlighting 5 characteristic peaks at 209 nm, 238 np, 289 nm, 302 nm and 318 nm.

Example 5 - Preparation and characterization of N (alpha-adamantanyl THA (C, _{.H 7R} N?) N (alpha-adamantanyl THA has the following structural formula:

1.08 g of alpha-bromo-ada antane (MW = 215) are dissolved in 20 ml of absolute ethyl alcohol.

1 g of THA base is dissolved separately in 25 ml of absolute ethyl alcohol. The two solutions previously obtained are mixed with magnetic stirring; a change in pH and an exothermic reaction are observed. The reaction is allowed to proceed for 30 min with stirring and then the excess alcohol is removed in a water bath under vacuum until dry. A product is obtained with a yield of approximately 95% in the form of a colorless microcrystalline powder, insoluble in water, soluble in alcohols, glycols and in acetone and having a melting point of 108 ° C.

The centesimal analysis gives the following results:

Carbon% 66.88

Hydrogen% 7.08

Nitrogen% 6.78

The infrared spectrum of this compound is shown in Figure 9.

Example 6 - Preparation and characterization of the N alpha-amino adamantanyl THA (Ct. E., H.)

The N alpha-amino adamantanyl THA can be represented by the following structural formula:

1.18 g of THA hydrochloride are introduced into a mortar with a capacity of 100 ml, which are finely pulverized, and then 0.94 g of alpha-amino adamantane hydrochloride is introduced in small portions. After mixing these two powders, spraying is continued for another 15 minutes in the cold.

The product obtained is in the form of fine colorless crystals soluble in alcohols, glycols and in water and having a melting point of 250 ° C. The centesimal analysis gives the following results:

Carbon% 65.25

Hydrogen% 7.87

Nitrogen% 9.94

The infrared spectrum of the product obtained is shown in Figure 10.

Example 7 - Preparation and characterization of N (is-atinyl-5 THA fd H ₁₇ N-, 0.)

The N (isatinyl-5) THA can be represented by the following structural formula:

d'une capacité de 100 ml, on introduit 1 g de THA fraîchement obtenue, finement pulvé¬ risée, puis par petites fractions, 1,13 g de bromo-5 isatine. On maintient la pulvérisation manuelle pendant 15 minutes de manière à obtenir une poudre fine microcristalline de couleur rouge vermillon. Le produit obtenu possède un point de fusion de 140°C, est insoluble dans l'eau mais est soluble dans les alcools, les glycols et dans l'acétone.

with a capacity of 100 ml, 1 g of freshly obtained THA, finely pulverized, is introduced, then in small fractions, 1.13 g of 5-bromo isatin. The manual spraying is maintained for 15 minutes so as to obtain a fine microcrystalline powder of vermilion red color. The product obtained has a melting point of 140 ° C, is insoluble in water but is soluble in alcohols, glycols and in acetone.

The centesimal analysis gives the following results:

Carbon% 59.48

Hydrogen% 4.8

Nitrogen% 9.91

The infrared spectrum of this compound is shown in Figure 11, and its UV spectrum is shown in Figure 12 on which we can note 5 characteristic peaks at 215.5 nm, 243.5 nm, 314.5 nm, 319.5 nm and 320.5 nm. Example 8 - Preparation and characterization of adenosinyl THA (C.. H ₇ N ₇ 0_) Adenosinyl THA can be represented by the following structural formula:

Is sprayed under the same conditions as in Examples 6 and 7 into a very fine microcrystalline powder, 1.35 g of adenosine base and 1.18 g of hydrated THA hydrochloride. The product obtained is in the form of fine colorless crystals soluble in alcohols, glycols in water and having a melting point of 203 ° C.

The centesimal analysis of this compound gives the following results:

Carbon% 55.07

Hydrogen% 5.62 Nitrogen% 19.55

The compound obtained has an infrared spectrum shown in Figure 13, and a UV spectrum shown in Figure 14 on which we will note characteristic peaks at 212.5 nm, 243.5 nm and 318.5 nm.

Example 9 - Preparation of quanosinyl THA (C.. H ₇₇ N ₇ 0.) Guanosinyl THA can be represented by the following structural formula:

The procedure is similar to that described in Examples 5 and 6. 1.42 of guanosine base and 1.18 g of THA hydrochloride are finely sprayed with a mortar.

The product obtained is in the form of fine colorless crystals soluble in alcohols, glycols in water and having a melting point of 208 ° C. The centesimal analysis gives the following results:

Carbon% 53.38 Hydrogen% 5.45 Nitrogen% 18.95

The infrared spectrum of the compound obtained is represented in FIG. 15 and the UV spectrum is represented in FIG. 16 on which we note characteristic peaks at 207 nm, 240.5 nm, 315 nm and 317 nm. Example 10 - Preparation and characterization of inosiny THA (C. HN * 0.) Inosinyl THA can be represented by the following developed formula:

The procedure is similar to that described in Examples 5 and 6, namely that one reduces to a fine powder, cold in a mortar, successively 1.18 g of THA hydrochloride and then gradually in small portions 1.35 g inosine base by extending the spray for 15 minutes. The product obtained is in the form of fine colorless crystals soluble in alcohols, glycols, in water and having a melting point of 216 ° C.

The centesimal analysis gives the following results: Carbon% 54.98

Hydrogen% 5.41 Nitrogen% 16.72

L'alpha-cétoglutarate de THA peut être représent par la formule suivante :

The infrared spectrum of the compound obtained is represented in FIG. 17 and its UV spectrum is represented on FIG. 18 on which we note characteristic peaks at 213.5 nm, 243.5 nm and 319.5 nm. Example 11 - Preparation and characterization of alpha-

The THA alpha-ketoglutarate can be represented by the following formula:

The method of preparation is similar to the method of preparation of the compound of Example 2, the parachlorophenoxyacetic acid being replaced by alpha-ketoglutaric acid and the mixture of this compound with THA being progressively

5 severely neutralized.

After hunting the excess ethanol, a white viscous mass is obtained.

The final compound is in the form of a microcrystalline powder or fine colorless crystals having a melting point of 122 ° C. The UV spectrum shows the characteristic bands of HAT. The infrared spectrum of the final compound is shown in Figure 19 and its Nuclear Magnetic Resonance spectrum is shown in Figure 20. Example 12 - Biological activity of HAT ascorbate a) Comparative study of the acute toxicity of ascorbate THA and THA hydrochloride

Lots of Swiss mice receive intraperitoneally (i.p.) a solution of THA ascorbate and THA hydrochloride at concentrations of 20, 30, 40, 50 and 60 mg / kg expressed as base.

At doses of 50 and 60 mg / kg, mortality is complete within one hour after administration of the two substances. The premortal symptoms are identical, both with THA and with THA ascorbate and correspond to cholinergic hyperactivity: tremors, convulsions, reflex hypersensitivity to shock and noise, intense sweating and salivation. Animals die in muscular hypertonia, with the post-mortem presence of myoclonus.

The calculated LDs are 37 mg for THA hydrochloride (total mortality at 50 mg and total survival at 20 mg / kg) and 26 mg for THA ascorbate.

The acute toxicity of ascorbate is therefore greater than that of hydrochloride taken in equimolecular doses, reported at the base. In both cases, mortality is observed within two hours of i.p. of the substance.

Conventionally, in humans, the therapeutic dose of HAT is 100 to 200 mg per 24 hours per os, or 1.6 to 3.2 mg / kg, which corresponds to about 1/12 of the LD 50 ( ip) in mice. Keeping the same ratio, the dosage would be 1 to 2 mg / kg for HAT ascorbate per day in humans, or 70 to 140 mg per 24 h. b) Comparative study of the hepatotoxicity of the ascorbate of THA and the hydrochloride of THA PRINCIPLE In the normal rat, no hepatotoxicity is noted after administration of purissima THA.

Complement irement, and for comparison purposes, cirrhosis is caused in rats by repeated injection of carbon tetrachloride in order to study on this model the ^~ s effects of THA in the form of hydrochloride or ascorbate.

EXPERIMENTAL PROTOCOL

30 long Evans rats (January) weighing between 450 and 550 g, 5 to 6 months old, are kept in the animal house for 1 month (temperature, humidity, ventilation controlled) and are divided into three lots of 10 by lot.

All the animals then receive orally for four days, at a rate of one administration per day (between 11 a.m. and 11:30 a.m.), 1.25 mg / kg of carbon tetrachloride mixed in equal parts with d oil. 'olive. On the third and fourth day, the animals receive intraperitoneally after the third administration of tetrachloride (1/2 h after) and 4 times (12 h, 20 h, 8 h, 16 h): - either physiological solution [ 1 ml / kg (10 rats)] or THA hydrochloride solution (2 mg / kg / ml) corresponding to 1.57 mg of THA in base form (10 rats) or THA ascorbate (2 mg / kg / ml) corresponding to 1.06 mg of HAT (10 rats)

One hour after the last intraperitoneal administration, the animals are examined for the establishment of a neurological score, then sacrificed (after weighing). A blood sample is taken, for the study of hepatic enzymes, on heparin, and the plasma, quickly separated after centrifugation, is stored at 0 ° C overnight.

The liver is observed macroscopically, and fixed in Bouin's medium and calcium formalin for subsequent microscopic study. RESULTS 1 - Study of the evolution of the weight of rats

Three rats died during the injection of carbon tetrachloride on D1, D2 and D3. In Table I are gathered the average weights of the rats before treatment and at the end of the treatments (in g): Table I: Evolution of the weight of the rats

Control HAT hydrochloride HAV ascorbate (8 rats) (9 rats) (9 rats) Before treatment 495 ± 10,487 ± 10,491 +.12

At the end of the treatments 464 + 10 454 ± 12 *. 453 ± 13 * P <0.05 - Comparison by Student's test between before and after treatment. The only difference observed between the three groups is due to hepatotoxicity by tetrachloride, which results in a weight loss of the order of 6 to 8%.

2 - Study of the macroscopic appearance of the liver After administration of tetrachloride, steatosis with cytolyuse develops gradually. On the fourth day, the appearance is characteristic in the control animals: an almost reddish-ocher-pink color, punctate granulations on all the lobes, sometimes hemorrhagic hematomas. It is not an alcoholic type cirrhosis, but rather a fatty type hepatitis.

Treatment with ascorbate or HAT hydrochloride does not significantly change the gross appearance of the liver.

3 - Study of the behavior and neurological activity of the rat

For each rat, the following reflexes have been studied with the rating below:

- normal corneal reflex 0 absent 1 for each eye

- normal ear response 0 absent 1 for each ear - normal grip reflex 1 absent 0 for each foreleg

- normal placement reaction 2 single leg 1 absent 0

- loss of normal support 1 absent 0 for each of the four legs

- righting reflex - normal 1 sow on back absent 0 fall falls on all fours 1 falls on the side 0 inclined plane balance tests returns in less than

15 seconds 2 from 15 to 30 s 1 more than 30 s 0 horizontal bar 1 - 0

- normal bending reflex 1 absent 0

- normal spontaneous mobility 2 reduced 1 absent 0 The normal score (sum of the scores) is 24 in young rats free of any pathology.

Table II collates the results given with carbon tetrachloride and the various treatments. Table II: Neurological score

- Rat tetrachloride only

(8 rats) - 18 ± 1

- Rat tetrachloride + THA

(9 rats) - 18 + 1

- Rat tetrachloride + HAT ascorbate

(9 rats) - 18 + 1

No difference is observed between the different treatments on the overall score, however, there is a difference concerning the mobility of rats which is quantified by the number of light rays crossed per minute in an optovarimeter (Optovarimex).

Table III: Spontaneous mobility of rats in an optovarimeter Mobility of rats (number of rays / min)

- Rat tetrachloride only

(8 rats) 224 + 15

- Rat tetrachloride + THA (9 rats) ** 140 ± 16

- Rat tetrachloride + HAT ascorbate

(9 rats) 229 ± 10

** P θ, 01 - Comparison with animals treated with carbon tetrachloride alone.

HAT causes a very significant decrease in spontaneous motor activity, the rats remain prostrate in the cage. HAT ascorbate does not have this action, no doubt due to the psychostimulatory action of ascorbate. 4 - Biological results on plasma

The following enzymes were measured: ASAT (Aspartate amino transferase) normal 0.28 IU / 1 ALAT (Alanine amino transferase) normal 0.44 IU / 1 P.OH (alkaline phosphatase) normal 0.69 IU / 1 GT (Glutamine transferase) normal 0.43 IU / 1

In Table IV are collected biological results. Table IV: Result of the hepatic enzyme assessment

ASAT ALAT P.OH 8 GT - tetrachloride only

(8 rats) 224 ± 15,761 + 212 135 ± 10 6 + 2

- tetrachloride + THA

(9 rats) 1591 ± 400 ** 1914 ± 471 146 ± 10 3 ± 1

- HAT tetrachloride + ascorbate

(9 rats) 680 + 99 814 + 144 161 ± 18 4 + 1 * P <0.05 - ** p <0.01

The injection of tetrachloride leads to an increase in the transaminases ASAT and ALAT as well as in alkaline phosphatase (P.OH). 0 conversely, the GT is not high, contrary to what is observed in the case of alcoholic cirrhosis. The model therefore concerns the activity and lysis of liver cells. The results of the above tests clearly show that THA ascorbate is less toxic than THA on liver cells already altered in vivo. c) Preliminary study on the treatment of AIDS patients with HAT ascorbate

The THA ascorbate obtained from purissime THA has very low hepatotoxicity. The activity on the cholinergic domain of HAT has been demonstrated in animals and in humans. HAT inhibits cholinesterase and increases the transfer of choline to the nerve endings.

The same is true for HAT ascorbate, which has a greater effect on retro-viruses. Its water-soluble dosage form allows intravenous infusions and injections in hospitals.

Applied to 20 patients with the HIV 1 virus (one of the viruses responsible for AIDS), HAT ascorbate has given very good results: increase in the number of CD 4 lymphocytes of the patients in significant proportions; decrease in antigens p 24, - regression of opportunistic diseases.

No hepatotoxicity was observed in the treated patients. THA ascorbate is as active as THA for the treatment of AIDS, in lower doses than base THA and it can be administered as an infusion thanks to its solubility in water, which has a big advantage. As previously mentioned, the dosage is 70 to 140 mg per 24 h.

Claims

CLAIMS 1. Chemical compounds derived from 5-amino 1,2,3,4-tetrahydroacridine (THA) corresponding to the general formula: I

in which: R represents a glycosyl group optionally substituted with a purine base, a thio-carbamyl group, in which case said group is common to two molecules of THA which are linked to it by the group -NH in position 5, - an optionally substituted adamantyl group, - an isatinyl group, - an alpha-ketoglutaryl group, an H ₂ Z group, in which Z represents a residue of a monoacid or of a diacid, in ionic form and linked in a non-covalent manner to the molecule of the compound, - a hydrogen atom, in which case the compound is present in the form of a complex comprising at least one THA molecule associated with at least one molecule chosen from alpha-adamantane, alpha-amino adamantane and a nucleoside such as l adenosine, guanosine or inosine. 2. Compounds according to claim 1, characterized in that R is different from H ₂ Z, and in that said compounds are in the form of pharmaceutically acceptable salts. 3. Compounds according to one of claims 1 or 2, characterized in that they are in the form of racemic mixtures or in the form of stereoisomers. 4. Compounds according to any one of the claims 1 to 3, characterized in that R is an ascorbyl group. 5. Compounds according to any one of claims 1 to 3, characterized in that R is an inosinyl, adenosinyl or guanidosinyl group, optionally substituted. 6. Compounds according to any one of claims 1 to 3, characterized in that R is a thio-carbamyl group, said compound being a di (tetrahydro 1, 2, 3, 4-acridinyl-5) thio urea. 7. Compounds according to any one of claims 1 to 3, characterized in that R is an alpha-adamantanyl group. 8. Compounds according to any one of claims 1 to 3, characterized in that R is an alpha-amino-adamantanyl group. 9. Compounds according to any one of claims 1 to 3, characterized in that R represents the group H ₂ Z, said compound being in the form of a pamoate salt. 10. Medicines containing at least one of the compounds according to any one of claims 1 to £ 11. Medicines containing at least the p-chlorophenoxyacetate salt of HAT. 12. Medicines according to one of claims 10 and 11, for the treatment of degenerative or atrophic diseases, in particular senile dementias of the Alzheimer type, multiple sclerosis, Duchesne's myopathy and AIDS. 13. Pharmaceutical composition, characterized in that it contains an effective amount of TH-p-chloro phenoxyacetate salt or of at least one compound according to any one of claims 1 to 9 in combination with one or more diluents or adjuvants compatible and pharmacologically acceptable. 14. Composition according to claim 13, characterized in that it is intended for the treatment of AIDS, Degenerative or atrophic diseases, in particular senile dementias of the Alzheimer type, multiple sclerosis, Duchesne's myopathy and others. 15. Pharmaceutical composition according to one of claims 13 or 14, presented for oral, parenteral or intravenous administration. 16. Method for the treatment of degenerative or atrophic diseases, in particular senile dementias of the Alzheimer type, multiple sclerosis, Duchesne's myopathy and AIDS by administration of at least one of the compounds according to one of claims 1 to 10 or a p-chlorophenoxyacetate salt of THA.